Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Research on monoclonal antibodies for the prevention and treatment of infections caused by flaviviruses (Dengue, Zika, West Nile, etc.) within the framework of Horizon Europe. Submission deadline: 13.04.2027.
Discover your potential with AI support
- Find out if this grant matches your project
- Develop your application together with AI
- Get matched with many more suitable grants
Grant criteria
Funding objective
The goal is the development of existing prophylactic and therapeutic monoclonal antibody candidates against one selected flavivirus each (Dengue, Zika, West Nile, Yellow Fever, TBE, or Japanese Encephalitis virus) through in vitro characterization, in vivo testing, GMP production, and initial clinical safety trials.
Eligible expenses
- Personnel costs
- Material costs
- Travel expenses
- Subcontractor services
Non-eligible expenses
- Retroactive costs
- Debt settlement
Eligible to apply
- Companies
- Educational Institutions
- Non-profit Organizations
- Public Institutions
Funding requirements
- Involvement of at least three independent legal entities from different EU Member States or Associated Countries
- Registration in the Participant Register (PIC)
- Compliance with ethical and security-related requirements
- No involvement of high-risk suppliers in the field of 5G security
Documents required for application
- Project description
- Financing plan
- Ethics self-assessment
- CVs of the project leaders
Evaluation criteria
- Excellence of the project
- Impact and exploitation potential
- Quality and efficiency of implementation
Description
Within the framework of Horizon Europe, the call "Development of monoclonal antibodies to prevent and treat infections from Flaviviruses" supports the preclinical and clinical development of prophylactic and therapeutic monoclonal antibody candidates against selected flaviviruses (including Dengue, Zika, West Nile, Yellow Fever, TBE, or Japanese Encephalitis viruses). Consortia consisting of at least three independent legal entities from different EU Member States or associated countries may submit up to 100% of their eligible costs – including personnel costs, material costs, travel expenses, and subcontractor services. Over a duration of 36 months with a financial framework between €9 million and €10 million per project, in vitro characterization, in vivo animal studies, GMP-compliant production, as well as initial clinical safety studies are funded. The application requires a project description, a financing plan, an ethics self-assessment, and the curricula vitae of the project leaders. The submission deadline is April 13, 2027, at 17:00 (Brussels time).
The evaluation is based on the criteria of Excellence, Impact, and Quality and Efficiency of Implementation with a maximum total score of 15 points. Projects must design an ethically and safety-compliant research approach, consider the gender aspect in antibody development, and involve relevant research infrastructures. A high level of technical maturity is demonstrated through structured project phases and a validated GMP production plan. Consortium partners – ranging from companies to universities and public institutions – benefit from a 100% funding rate guarantee and may submit their funding applications from the call opening on February 10, 2027, upon positive evaluation.